Vitreosolve

A
Potential Preventative Treatment
for Diabetic Retinopathy now in phase 3 FDA clinical trials.

Research has shown that the vitreous may be the key to the development of PDR. The interior portion of the human eye is filled with a gelatinous substance called vitreous. It occupies approximately 80% of the volume of the eyeball and is formed by a network of transparent collagen fibrils. This gives the vitreous the consistency of firm cold Jell-O. With time, the vitreous gel liquefies and eventually pulls away or separates from the back of the eye where it is attached to the retina. This process is called POSTERIOR VITREOUS RETRACTION OR DETACHMENT (PVD) and is a common event occurring in normal people somewhere between 40-70 years of age. When the vitreous separates (PVD), patients are less prone to develop proliferative diabetic retinopathy. One study reported that the presence of a PVD modifies or protects against the progression of Proliferative diabetic retinopathy (PDR). In another study, patients with non-proliferative diabetic retinopathy (NPDR) were followed for and average of 32 months. Data from those with POSTERIOR VITREOUS RETRACTIONS suggest subjects were seven times less likely to develop the more severe form of retinopathy, PDR.

How does VITREOSOLVE work?
VITREORETINAL TECHNOLOGIES, INC knew that the naturally occurring process; PVD was decreasing the likelihood of vision loss from diabetic retinopathy. They decided to develop a safe and effective drug to duplicate this process, thus VITREOSOLVE was born. Vitreosolve is injected into the vitreous cavity of the eye liquefying the vitreous gel. Once the vitreous gel is liquefied the new vessels produced with proliferative disease are no longer are able to use the firm structure or scaffolding of the vitreous to grow into the retina. Without retinal vascularization vision loss from diabetic retinopathy is significantly reduced. Therefore data suggests VITREOSOLVE IS A POTENTIAL PREVENTATIVE TREATMENT. It is designed to be administered before new vessels develop to minimize the vessels destructive effect that will likely follow.

HOW DOES THIS HELP US OUT NOW?
Unfortunately we have to either wait until this therapy is FDA approved or enter the study. The information below may help:

Top of Page

Hit Counter